Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Statements for the Second Quarter of the Fiscal Year Ending March 31, 2027 [Japanese GAAP]

November 9, 2026

Company Name VITAL KSK HOLDINGS, INC. Stock Exchange Listing Tokyo
Code Number 3151 URL https://www.vitalksk.co.jp/
Representative (Title) President & CEO (Name) Taisuke Murai
Contact (Title) Director of Accounting & Finance (Name) Isao Kita (TEL) +81-3-5787-8565
Scheduled date of filing quarterly report November 13, 2026 Scheduled date of commencing dividend payments December 3, 2026
Preparation of supplementary explanatory materials : Yes
Financial results briefing : Yes (for institutional investors and analysts)

(Amounts of less than one million yen are rounded down.)

1. Consolidated Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to September 30, 2026)

(1) Consolidated Operating Results (Cumulative)

(% indicates changes from the previous interim period.)

	Net sales		Core operating profit		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended September 30, 2026	309,806	3.2	1,397	(37.4)	600	(63.4)	1,138	(77.4)	462	(90.7)
Six months ended September 30, 2025	300,234	1.1	2,233	-	1,641	(42.9)	5,042	38.6	4,968	105.2

(Note) Comprehensive income: Six months ended September 30, 2026: 1,310 Million yen ((62.4)%); Six months ended September 30, 2025: 3,485 Million yen ((45.2)%)

	Quarterly earnings per share	Diluted quarterly earnings per share
	Yen	Yen
Six months ended September 30, 2026	9.63	-
Six months ended September 30, 2025	102.84	-

(Note) Regarding core operating profit, please refer to "1. Qualitative Information on Quarterly Financial Results, Explanation of Operating Results."

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
Six months ended September 30, 2026	329,422	116,885	35.0
Fiscal Year 2026	320,568	118,707	36.6

(Reference) Equity: Six months ended September 30, 2026: 115,372 Million yen; Fiscal Year 2026: 117,223 Million yen

2. Cash Dividends

	Annual dividends				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year 2026	-	34.00	-	36.00	70.00
Fiscal Year Ending March 31, 2027	-	35.00			
Fiscal Year 2027 (Forecast)			-	35.00	70.00

(Note) 1. Revision to the forecast for dividends announced most recently : None

3. Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027 (From April 1, 2026 to March 31, 2027)

(% indicates changes from the previous fiscal year)

	Net sales		Core operating profit		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	627,000	2.7	3,400	(35.9)	1,800	(55.3)	2,700	(65.5)	6,700	(9.0)	138.50

(Note) Revision to the forecast of consolidated results announced most recently :Yes

For the consolidated earnings forecast, please refer to the "Notice Regarding Revision of Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2027" released today (November 9, 2026).

* Notes

(1) Significant changes in the scope of consolidation during the current interim period : None

(2) Application of specific accounting procedures for the preparation of interim consolidated financial statements : Yes

(Note) For details, please refer to page 10 of the attached materials, "(4) Notes to Interim Consolidated Financial Statements (Application of specific accounting procedures for the preparation of interim consolidated financial statements)."

(3) Changes in accounting policies, changes in accounting estimates and retrospective restatement

(i) Changes in accounting policies due to the revision of accounting standards : Yes

(ii) Changes in accounting policies other than (i) above : None

(iii) Changes in accounting estimates : None

(iv) Restatements : None

(4) Total number of outstanding shares (common shares)

(i) Total number of outstanding shares (including treasury shares)	Six months ended September 30, 2026	51,902,976 shares	Fiscal Year 2026	51,902,976 shares
(ii) Total number of treasury shares	Six months ended September 30, 2026	4,405,798 shares	Fiscal Year 2026	3,525,894 shares
(iii) Average number of shares during the period (interim period)	Six months ended September 30, 2026	48,018,049 shares	Six months ended September 30, 2025	48,312,867 shares

* The quarterly (interim) financial results are outside the scope of review by certified public accountants or audit corporations.

* Explanation of the proper use of performance forecast and other notes

・The earnings forecasts and other forward-looking statements herein are based on information currently available to the Company and certain assumptions deemed reasonable. Actual results may differ significantly from these forecasts due to various factors.

・The Company plans to hold a financial results briefing for institutional investors and analysts on November 12, 2026. The presentation materials to be used on that day will be posted on the Company's website promptly after the briefing.

○ Table of Contents

1. Qualitative Information on Quarterly Financial Results 2
Explanation of Operating Results 2
2. Interim Consolidated Financial Statements and Primary Notes 4
(1) Interim Consolidated Balance Sheets 4
(2) Interim Consolidated Statements of Income and Interim Consolidated Statements of Comprehensive Income 6
(3) Interim Consolidated Statements of Cash Flows 8
(4) Notes to Interim Consolidated Financial Statements 10
(Notes on going concern assumption) 10
(Notes in the case of significant changes in amount of shareholders' equity) 10
(Changes in accounting policies) 10
(Application of specific accounting procedures for the preparation of interim consolidated financial statements) 10
(Segment information) 10

1. Qualitative Information on Quarterly Financial Results

Explanation of Operating Results

During the first quarter of the current consolidated fiscal year, the global economic outlook has become increasingly uncertain due to concerns over rising resource distribution and logistics costs accompanying heightened geopolitical risks, as well as trends in U.S. trade policy. In the Japanese economy, although there are signs of improvement in corporate earnings and wage increases, uncertainty in the business environment has reached unprecedented levels due to a wide range of concerns, including the impact of large-scale natural disasters, cybersecurity threats, exchange rate fluctuations, and volatility in financial and capital markets. Overall, the economic outlook remains extremely difficult to predict.

In the pharmaceutical wholesale industry, which is the Group's main business, although drug prices were lowered due to the April 2026 drug price revision, it is expected that discussions will intensify toward a drastic reform of policies and systems related to people's lives and health, and the policy of curbing drug costs is expected to continue.

In addition, rising costs across all industries, such as the continued trend of inflation and increased investment in cybersecurity, are the main factors pushing up the costs of pharmaceutical distribution. Furthermore, profits continue to be squeezed by intensifying market competition, rising purchase prices, and declining rebates. While major drug patents are expiring and the use of generic drugs is being promoted, the focus of new drugs being launched is shifting to specialty pharmaceuticals. In the pharmaceutical wholesale business, there is a growing demand for advanced information-provision and logistics capabilities.

Under these circumstances, the Company launched the "Medium-Term Management Plan 2027 -Move on to the Next Stage-" (FY2025-FY2027) in April 2025. As a company listed on the Tokyo Stock Exchange Prime Market, the Company has fully adopted the concept of group management with a focus on capital cost, aiming to achieve sustainable growth for the Group and enhance corporate value over the medium to long term, by working on strengthening the profitability of existing businesses and reviewing the businesses themselves, in addition to making aggressive investments for growth. Among these initiatives, one of the Group's major challenges is the "Pharmaceutical Business (business of supporting introduction of unapproved drugs)," for which the Company newly established MEDLEAP PHARMA COMPANY LIMITED (a consolidated subsidiary of the Company) on September 16, 2025. Regarding the development of its new drug candidate "Ferric Maltol (Development Code: ST10)," patient enrollment is progressing smoothly in the domestic Phase 2 clinical trial targeting Pulmonary Arterial Hypertension, and we are preparing for the start of Phase 3 trials. In addition, we announced the start of an exploratory Phase 2 clinical trial targeting "Pulmonary Hypertension associated with Chronic Lung Disease (emphysematous lesions and/or interstitial lesions)" from November 2026. (For details, please refer to the announcement disclosed on November 9, 2026, titled "Notice Regarding the Start of Domestic Phase 2 Clinical Trial of 'Ferric Maltol (Development Code: ST10)' by Consolidated Subsidiary (MEDLEAP PHARMA COMPANY LIMITED) Aiming for Additional Indication for Pulmonary Hypertension associated with Chronic Lung Disease.") We believe this is an important initiative that aims to contribute to expanding treatment options for patients and will lead to strengthening the Group's future growth foundation. Furthermore, as part of our efforts to enhance logistics functions, the Isehara Logistics Center of VITAL-NET, Inc. (Isehara City, Kanagawa Prefecture) was completed on April 9, 2026. This facility is equipped with high-quality logistics functions that comply not only with GDP standards for pharmaceutical distribution but also with GMP standards for pharmaceutical manufacturing. We are positioning this facility as the core of our 3PL business (Note 1) and are striving for further expansion. At KSK CO., LTD., in addition to maintaining and improving a safe, secure, and stable pharmaceutical distribution system, we have completed the introduction of electronic product receipts at all sales branches, which we have been implementing in stages since the previous fiscal year, to promote significant operational efficiency. Going forward, through the full-scale operation of this system, we will aim for further sophistication of logistics processes and efficiency in business operations. In addition, at the Women's Healthcare Solutions Department, which aims to solve diverse health issues for women, we launched our own e-commerce site "Elcare store" on April 9, 2026, which handles femtech and femcare products. We are expanding our services based on the concepts of "providing reliable information supervised by doctors," "product selection utilizing expertise in the medical industry," and "proposing 'care that can be continued'." At the same time, we have been actively engaged in disease awareness activities in the gynecological field, including the screening of cervical cancer awareness videos on the large "Tonbori Station" screen on the streets of Dotonbori. We aim to be a presence that supports each woman in both mind and body, and we will continue to strive to expand our product lineup and enhance our services.

Regarding the performance for the six months ended September 30, 2026, net sales were 309,806 million yen (103.2% of the same period of the previous year), and operating profit was 600 million yen (36.6% of the same period of the previous year). In addition,

core operating profit (Note 2), which is before deducting "research and development expenses" in the new pharmaceutical business (business of supporting introduction of unapproved drugs), was 1,397 million yen (62.6% of the same period of the previous year). Ordinary profit was 1,138 million yen (22.6% of the same period of the previous year), and profit attributable to owners of parent was 462 million yen (9.3% of the same period of the previous year).

Note 1: 3PL business: A business in which the Group comprehensively undertakes everything from logistics planning and design to execution on behalf of pharmaceutical companies.

Note 2: Starting from the previous fiscal year, in addition to the conventional "operating profit," we calculate "core operating profit," which is before deducting "research and development expenses," as an indicator of the profitability of our ongoing business.

Performance by segment is as follows.

(i) Pharmaceutical Wholesale Business

In the pharmaceutical wholesale business, although there were negative impacts from the drug price revision, revenue increased due to efforts to focus on the sale of products eligible for the Patent-period price Maintenance Program for Innovative Drugs (PMP), mainly anticancer drugs, and influenza vaccines. On the profit side, segment profit decreased due to a decline in the gross profit margin resulting from intensifying market competition, rising purchase prices, and lower rebates, as well as an increase in selling, general and administrative expenses due to higher personnel costs and rising prices. Furthermore, expenses increased due to various upfront investments for the future, including DX promotion, and the strengthening of cybersecurity measures.

As a result of the above, net sales were 291,058 million yen (103.2% of the same period of the previous year), and segment profit (operating profit) was 1,523 million yen (73.2% of the same period of the previous year).

(ii) Pharmacy Business

In the pharmacy business, although we worked to calculate dispensing fees through new store openings and the strengthening of family pharmacy functions, revenue decreased as we were unable to cover the impact of a decline in the number of prescriptions received due to the trend toward longer prescription durations. On the profit side, the segment recorded a loss due to an increase in costs resulting from higher personnel costs and rising prices. As a result of the above, net sales were 9,851 million yen (99.8% of the same period of the previous year), and segment loss (operating loss) was 55 million yen (segment profit of 135 million yen for the same period of the previous year).

(iii) Veterinary Drug Wholesale Business

In the Veterinary Drug Wholesale Business, revenue decreased as sales competition remained severe. On the profit side, profit increased as a result of efforts to manage delivery prices and costs. As a result of the above, net sales were 6,080 million yen (98.4% of the same period of the previous year), and segment profit (operating profit) was 111 million yen (103.1% of the same period of the previous year).

(iv) Pharmaceutical Business (business of supporting introduction of unapproved drugs)

The Pharmaceutical Business (business of supporting introduction of unapproved drugs) is a new business launched in September 2025, and no sales were posted in the six months ended September 30, 2026, while expenses necessary for business activities including research and development expenses came to 856 million yen, and segment loss amounted to the same amount of 856 million yen.

(v) Nursing Care-related Rental and Other Business

In the Nursing Care-related Rental and Other Business, revenue increased due to factors including the consolidation of Yachiyo Care Holdings Co., Ltd. in December 2025. On the profit side, segment loss increased due to higher selling, general and administrative expenses resulting from rising personnel costs and inflation. As a result, net sales were 2,816 million yen (127.0% of the same period of the previous year), and segment loss (operating loss) was 218 million yen (segment loss of 122 million yen for the same period of the previous year).

2. Interim Consolidated Financial Statements and Primary Notes

(1) Interim Consolidated Balance Sheets

(Million yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	22,953	21,024
Notes and accounts receivable - trade	121,233	126,886
Inventories	33,283	35,514
Accounts receivable - other	12,825	15,229
Other	4,662	4,351
Allowance for doubtful accounts	(52)	(62)
Total current assets	194,905	202,943
Non-current assets		
Property, plant and equipment		
Buildings and structures (net)	20,851	20,405
Land	24,651	24,688
Other (net)	5,488	6,196
Total property, plant and equipment	50,990	51,290
Intangible assets		
Goodwill	2,646	2,479
Other	4,240	3,798
Total intangible assets	6,887	6,277
Investments and other assets		
Investment securities	53,057	54,438
Other	15,311	15,089
Allowance for doubtful accounts	(583)	(617)
Total investments and other assets	67,785	68,911
Total non-current assets	125,662	126,479
Total assets	320,568	329,422

(Million yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	169,767	179,261
Short-term borrowings	950	950
Current portion of long-term borrowings	984	1,676
Income taxes payable	2,537	1,007
Provision for bonuses	1,579	1,635
Other	7,401	6,952
Total current liabilities	183,219	191,484
Non-current liabilities		
Long-term borrowings	3,893	6,116
Other provisions	231	176
Retirement benefit liability	427	228
Other	14,090	14,531
Total non-current liabilities	18,642	21,052
Total liabilities	201,861	212,536
Net assets		
Shareholders' equity		
Share capital	5,000	5,000
Capital surplus	5,302	5,315
Retained earnings	81,013	79,746
Treasury shares	(3,960)	(5,371)
Total shareholders' equity	87,355	84,690
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	27,438	28,421
Remeasurements of defined benefit plans	2,429	2,259
Total accumulated other comprehensive income	29,867	30,681
Non-controlling interests	1,483	1,513
Total net assets	118,707	116,885
Total liabilities and net assets	320,568	329,422

(2) Interim Consolidated Statements of Income and Interim Consolidated Statements of Comprehensive Income

Interim Consolidated Statements of Income

(Million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales	300,234	309,806
Cost of sales	276,404	285,464
Gross profit	23,829	24,342
Selling, general and administrative expenses	22,188	23,741
Operating profit	1,641	600
Non-operating income		
Gain on investments in investment partnerships	2,841	8
Interest income	23	30
Dividend income	346	405
Share of profit of entities accounted for using equity method	29	23
Rental income	129	121
Other	129	122
Total non-operating income	3,500	712
Non-operating expenses		
Interest expenses	32	45
Rental expenses	28	35
Loss on investments in investment partnerships	20	55
Other	17	38
Total non-operating expenses	98	174
Ordinary profit	5,042	1,138
Extraordinary income		
Gain on sale of non-current assets	9	139
Gain on sale of investment securities	2,518	59
Gain on sale of investments in capital	-	52
Other	54	-
Total extraordinary income	2,581	251
Extraordinary losses		
Loss on sale of non-current assets	-	30
Impairment losses	89	21
Other	7	2
Total extraordinary losses	96	54
Profit before income taxes	7,527	1,336
Income taxes	2,527	839
Profit	5,000	496
Profit attributable to non-controlling interests	31	33
Profit attributable to owners of parent	4,968	462

Interim Consolidated Statements of Comprehensive Income

(Million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit	5,000	496
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,499)	752
Remeasurements of defined benefit plans	(64)	(170)
Share of other comprehensive income of entities accounted for using equity method	49	231
Total other comprehensive income	(1,514)	813
Comprehensive income	3,485	1,310
(Breakdown)		
Comprehensive income attributable to owners of parent	3,453	1,276
Comprehensive income attributable to non-controlling interests	31	33

(3) Interim Consolidated Statements of Cash Flows

(Million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before income taxes	7,527	1,336
Depreciation	1,826	2,017
Impairment losses	89	21
Amortization of goodwill	72	167
Increase (decrease) in allowance for doubtful accounts	(79)	43
Increase (decrease) in provision for bonuses	(135)	54
Increase (decrease) in retirement benefit liability	(209)	(149)
Interest and dividend income	(369)	(435)
Rental income	(129)	(121)
Interest expenses	32	45
Share of loss (profit) of entities accounted for using equity method	(29)	(23)
Loss (gain) on sale and valuation of investment securities	(2,518)	(59)
Loss (gain) on sale and retirement of property, plant and equipment	(7)	(107)
Decrease (increase) in trade receivables	(9,420)	(5,614)
Decrease (increase) in inventories	(228)	(2,217)
Decrease (increase) in accounts receivable - other	(126)	(2,376)
Decrease (increase) in guarantee deposits	43	175
Increase (decrease) in trade payables	12,223	9,419
Other	(3,153)	1,404
Subtotal	5,407	3,578
Interest and dividends received	368	435
Interest paid	(32)	(45)
Income taxes paid	(1,433)	(2,355)
Income taxes refund	4	1
Other	5	28
Cash flows from operating activities	4,319	1,644

(Million yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from investing activities		
Net decrease (increase) in time deposits	(550)	(100)
Purchase of property, plant and equipment	(1,017)	(2,628)
Proceeds from sale of property, plant and equipment	25	335
Purchase of intangible assets	(1,034)	(421)
Purchase of investment securities	(351)	(29)
Proceeds from sale of investment securities	877	76
Proceeds from redemption of investment securities	-	10
Loan advances	(219)	(31)
Proceeds from collection of loans receivable	6	19
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(172)	-
Other	230	158
Cash flows from investing activities	(2,205)	(2,611)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(20)	-
Proceeds from long-term borrowings	-	3,500
Repayments of long-term borrowings	(492)	(580)
Repayments of lease liabilities	(453)	(311)
Purchase of treasury shares	(0)	(1,452)
Increase (decrease) in money held in trust for purchase of treasury shares	-	(491)
Dividends paid	(1,157)	(1,741)
Other	(4)	(4)
Cash flows from financing activities	(2,127)	(1,081)
Net increase (decrease) in cash and cash equivalents	(14)	(2,047)
Cash and cash equivalents at beginning of period	20,214	19,437
Increase in cash and cash equivalents resulting from merger with non-consolidated subsidiaries	-	19
Cash and cash equivalents at end of period	20,200	17,409

(4) Notes to Interim Consolidated Financial Statements

(Notes on going concern assumption)

Six months ended September 30, 2026

Not applicable.

(Notes in the case of significant changes in amount of shareholders' equity)

Six months ended September 30, 2026

Not applicable.

(Changes in accounting policies)

(Implementation Guidance on Accounting for Financial Instruments)

The "Implementation Guidance on Accounting for Financial Instruments" (Implementation Guidance No. 9, March 11, 2025) has been applied from the beginning of the interim consolidated fiscal period. There is no impact on the interim consolidated financial statements.

(Application of Accounting Standards for Interim Financial Statements, etc.)

The "Accounting Standard for Interim Financial Statements" (ASBJ Statement No. 37, October 16, 2025) and the "Implementation Guidance on Accounting Standard for Interim Financial Statements" (ASBJ Guidance No. 34, October 16, 2025) have been applied from the beginning of the current interim consolidated fiscal period. There is no impact on the interim consolidated financial statements.

(Accounting policies adopted specially for the preparation of interim consolidated financial statements)

Calculation of tax expenses

Tax expenses are calculated by the method in which the effective tax rate on profit before income taxes for the current consolidated fiscal year after application of tax effect accounting is reasonably estimated, and profit before interim income taxes for the interim period is multiplied by the estimated effective tax rate.

(Segment information)

(Segment information)

1. Overview of reportable segments

The Group's reportable segments are components of the Group about which separate financial information is available. These segments are subject to periodic examinations to enable the company's Board of Directors to decide how to allocate resources and assess performance.

The Group’s segment is categorized based on the business of its operating company, and thus its main segments, the “Pharmaceutical Wholesale Business,” the “Pharmacy Business,” the “Veterinary Drug Wholesale Business,” the “Pharmaceutical Business,” and the “Nursing Care-related Rental and Other Business” comprise the Group’s reportable segments.

The “Pharmaceutical Wholesale Business” is engaged in sales of drugs, diagnostic products, medical devices, materials, etc. to medical institutions, such as hospitals, clinics, and pharmacies. The “Pharmacy Business” is engaged in sales of drugs, medical devices and equipment, and hygiene materials, etc. to general consumers. The “Veterinary Drug Wholesale Business” is engaged in sales of veterinary drugs, feeds, etc. to farms, ranches, veterinary hospitals, clinics, etc. In the “Pharmaceutical Business,” the Company engages in providing support, etc. for the introduction of new drugs that are not yet approved in Japan but have been approved in Europe and the United States. The “Nursing Care-related Rental and Other Business” includes nursing care-related rental business, nursing care service business, wholesale business handling agricultural chemicals, etc., transport business, sports-related facility operating business and consulting business for medical institutions.

2. Method of measurement for the amounts of net sales, profit (loss), assets and other items for each reportable segment

The method of accounting for the reportable business segments is generally the same as those stated in "Basis for the Presentation of the Consolidated Financial Statements."

Profit in the reportable segments is based on operating profit.

Inter-segment revenues and transfers are calculated at prevailing market prices.

3. Information on net sales, profit (loss), assets and other items by reportable segment

Six months ended September 30, 2025

(Million yen)

	Reportable segment					
	Pharmaceutical Wholesale Business	Pharmacy Business	Veterinary Drug Wholesale Business	Pharmaceutical Business	Nursing Care-related Rental and Other Business	Total
Net sales						
Net sales to outside customers	281,967	9,870	6,178	-	2,217	300,234
Inter-segment net sales or transfers	5,465	6	0	-	1,386	6,857
Total	287,432	9,876	6,178	-	3,603	307,092
Segment profit or loss (△)	2,080	135	108	(592)	(122)	1,609

	Adjustment (Note 1, 2)	Amount recorded in quarterly consolidated statements of income (Note 3)
Net sales		
Net sales to outside customers	-	300,234
Inter-segment net sales or transfers	(6,857)	-
Total	(6,857)	300,234
Segment profit or loss (△)	31	1,641

(Note) 1. Adjustment of sales of (6,857) million yen was mainly due to the elimination of intersegment transactions.

2. Adjustment of segment profit (loss) of 31 million yen refers to elimination of inter-segment transactions.

3. Adjustments are made to reconcile segment income (loss) to operating profit reported on the quarterly consolidated statements of income.

Six months ended September 30, 2026

(Million yen)

	Reportable segment					
	Pharmaceutical Wholesale Business	Pharmacy Business	Veterinary Drug Wholesale Business	Pharmaceutical Business	Nursing Care-related Rental and Other Business	Total
Net sales						
Net sales to outside customers	291,058	9,851	6,080	-	2,816	309,806
Inter-segment net sales or transfers	5,502	6	0	-	1,448	6,957
Total	296,560	9,857	6,080	-	4,265	316,763
Segment profit or loss (△)	1,523	(55)	111	(856)	(218)	504

	Adjustment (Note 1, 2)	Amount recorded in quarterly consolidated statements of income (Note 3)
Net sales		
Net sales to outside customers	-	309,806
Inter-segment net sales or transfers	(6,957)	-
Total	(6,957)	309,806
Segment profit or loss (△)	96	600

(Note) 1. Adjustment of sales of (6,957) million yen was mainly due to the elimination of intersegment transactions.

2. Adjustment of segment profit (loss) of 96 million yen refers to elimination of inter-segment transactions.

3. Adjustments are made to reconcile segment income (loss) to operating profit reported on the quarterly consolidated statements of income.